Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab

Francesco Menzella, Maria Aliani, Elena Altieri, Pietro Bracciale, Stefano Centanni, Fausto De Michele, Fabiano Di Marco, Girolamo Pelaia, Micaela Romagnoli, Pietro Schino, Silvia Boarino, Gianfranco Vitiello, Paola Rogliani
European Respiratory Journal 2021 58: PA3735; DOI: 10.1183/13993003.congress-2021.PA3735
Francesco Menzella
1Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia- IRCCS, Reggio Emilia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Francesco.Menzella@ausl.re.it
Maria Aliani
2Istituti Clinici Scientifici Maugeri IRCCS, Respiratory Rehabilitation Unit of the Institute of Cassano Delle Murge, Bari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Altieri
3Reparto di Pneumologia, P.O. Garbagnate Milanese, Garbagnate Milanese (MI), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pietro Bracciale
4Reparto di Pneumologia, Ospedale Ostuni, Ostuni (BR), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Centanni
5Respiratory Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milano, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fausto De Michele
6UOC Pneumologia e Fisiopatologia Respiratoria, AORN A. Cardarelli, Napoli, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabiano Di Marco
7Department of Health Sciences, University of Milan, Pneumology, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Girolamo Pelaia
8Dipartimento di Scienze della Salute, Università Magna Graecia, Catanzaro, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Micaela Romagnoli
9UOC Pneumologia, ULSS 2 Marca Trevigiana, Treviso, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pietro Schino
10Unit of Respiratory Physiopathology, Miulli General Hospital, Acquaviva delle Fonti, Bari, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Boarino
11AstraZeneca Italy, Basiglio (MI), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianfranco Vitiello
11AstraZeneca Italy, Basiglio (MI), Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Rogliani
12Division of Respiratory Medicine, University Hospital "Tor Vergata", Rome, Italy; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Roma, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Safety and efficacy of benralizumab (BEN) for severe eosinophilic asthma (SEA) have been demonstrated in Phase III clinical trials. Obesity is a risk factor for SEA and might affect the beneficial effect of asthma medication. ANANKE is part of AstraZeneca’s global XALOC real-world evidence program for benralizumab.

Aims: To explore whether benralizumab efficacy is affected by body mass index (BMI) in SEA patients.

Methods: Post-hoc analysis of an observational, multicenter, retrospective Italian study of SEA patients with at least 12 weeks of BEN treatment. Patients were stratified according to BMI: normal/underweight (Nr) (BMI<25), overweight (OW) (BMI 25-29) and obese (Ob) (BMI≥30). Clinical features, asthma control (ACT) and annualized exacerbation rates (AER) reported in the three groups before and after BEN administration.

Results: 182 patients were included, Nr=70 (68.6% female, mean age 55±12.8, median BEN duration 9.2 months), OW=79 (48.1% female, mean age 56.6±12.9, median BEN duration 9.4 months), Ob=33 (75.8% female, mean age 56.5±14.7, median BEN duration 10.2 months). Any AER passed from 4.49 to 0.18 (-96%) in Nr (N=66), from 3.99 to 0.32 (-92%) in OW (N=76) and from 3.72 to 0.34 (-90.9%) in Ob (N=30). Severe AER changed from 1.32 to 0.04 (-97%) in Nr, from 1.12 to 0.10 (-91.1%) in OW and from 1.13 to 0.08 (-92.9%) in Ob. ACT increased from a median of 15 in Nr (N=57), 14 in OW (N=61) and 13 in Ob (N=25) to 22 in Nr (N=29) and Ob (N=11) and 23 in Ow (N=35) at week 48.

Conclusions: In an Italian real-world setting, the efficacy of BEN in SEA patients seems not to be affected by obesity, leading to asthma control al >90% reduction of AER and severe AER regardless of BMI.

  • Treatments
  • Severe asthma
  • Asthma - management

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3735.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
Francesco Menzella, Maria Aliani, Elena Altieri, Pietro Bracciale, Stefano Centanni, Fausto De Michele, Fabiano Di Marco, Girolamo Pelaia, Micaela Romagnoli, Pietro Schino, Silvia Boarino, Gianfranco Vitiello, Paola Rogliani
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3735; DOI: 10.1183/13993003.congress-2021.PA3735

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
Francesco Menzella, Maria Aliani, Elena Altieri, Pietro Bracciale, Stefano Centanni, Fausto De Michele, Fabiano Di Marco, Girolamo Pelaia, Micaela Romagnoli, Pietro Schino, Silvia Boarino, Gianfranco Vitiello, Paola Rogliani
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3735; DOI: 10.1183/13993003.congress-2021.PA3735
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
  • Identifying super-responders to benralizumab in severe asthma
  • Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Show more Airway pharmacology and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society